Novo Nordisk Investors Skeptical of New Drug Pipeline
· Business · Wall Street Journal, CNBC
Novo Nordisk is banking on its new drug pipeline to compete with Eli Lilly in the weight-loss market, though investors remain unconvinced by the strategy. The company behind Wegovy faces intense pressure to maintain its market position as rivals introduce competing treatments. While Novo Nordisk continues to develop new therapies, market participants have expressed doubt regarding the potential success of these upcoming products. The company's future growth depends on its ability to prove the efficacy of these new drugs against established and emerging competitors.
Why it matters
The competition between Novo Nordisk and Eli Lilly dictates the trajectory of the multi-billion dollar weight-loss drug market, impacting global healthcare investment trends.
Read the original report — Wall Street Journal
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.